“STDs, pregnancy: Kids need clinical, scientific support - Moultrie Observer” plus 4 more |
- STDs, pregnancy: Kids need clinical, scientific support - Moultrie Observer
- Don't block folic acid in early pregnancy - PhysOrg
- INSIDE STORY: Padma Lakshmi's 'Miracle Pregnancy' - People
- LETTER: Some of us do know the facts - Lufkin Daily News
- Basilea's Toctino - Market Wire
STDs, pregnancy: Kids need clinical, scientific support - Moultrie Observer Posted: 13 Oct 2009 07:28 PM PDT Published October 13, 2009 10:22 pm - On this page today is a well-written piece on sex education from the viewpoint of a teen-ager. It is great food for thought. We should pay attention and respond with more logical and clinical approaches to a serious issue. STDs, pregnancy: Kids need clinical, scientific support
On this page today is a well-written piece on sex education from the viewpoint of a teen-ager. It is great food for thought. We should pay attention and respond with more logical and clinical approaches to a serious issue. Too long we have buried our heads in the sand with "abstinence only" sex education. Meanwhile, record teen-age pregnancies are being recorded and the cases of sexually transmitted diseases (STDs) are increasing. While promoting abstinence as the only way to confront these issues is a noble cause (and perhaps it even works in some instances) it has not been a great success story. It's time that we equipped our young people with appropriate clinical knowledge about STDs as opposed to allowing misinformation and scare tactics to prevail in this venue of social interaction. As is pointed out in this guest column, youngsters are ill-equipped with knowlege about STDs. When it comes to HIV/AIDS, some are being given information by adults that also is faulty. Misinformation is seldom a good thing, especially when it comes to one's health. For instance, it was once believed that a simple kiss coiuld transmit HIV. For the most part that idea is debunked by volumes of research, much of it available on the Internet (through credited research programs). That's not too say that there aren't special but rare circumstances when such is possible, but it's not probable. Yet there are specific documented ways the virus can be transmitted and our youth should know the facts. In heterosexual activity, females should know that they are much more vulnerable to HIV infection than a male. Again, that doesn't mean it's impossible for the male to be infected, it just means the chances are reduced for the male in these circumstances and research explains why. Research also notes that properly used condoms make it very low risk for the transmission of most STDs. As well, they can help prevent pregnancy. While abstinence is the only absolute preventative in this regard, we must face the fact that humans are sexual beings. And as this young lady's column points out, young sexual beings are better protected with good clinical advice as a tandem to the encouragement of abstinence. Accurate, scientific and clinical information that is properly dispensed could do much to slow the spread of STDS and perhaps reduce the number of teen-age pregnancies. Most health experts will agree with this. If we continue to embrace the notion that promoting abstinence alone is the best way to address this issue, then we will continue to see rising statistics that describe rates of STDs and teen pregnancy. Time to take our heads out of the sand. This content has passed through fivefilters.org. |
Don't block folic acid in early pregnancy - PhysOrg Posted: 13 Oct 2009 08:47 PM PDT Don't block folic acid in early pregnancyOctober 13th, 2009Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007. The study drew information from 84,832 babies born at Soroka Medical Center, in Beer-Sheva, Israel. It was carried out as part of the PhD dissertation of Mgr. Ilan Matok, supervised by principal investigators Dr. Amalia Levy and Prof. Rafael Gorodischer from Ben-Gurion University of the Negev in Israel, in collaboration with the Division of Clinical Pharmacology, Hospital for Sick Children in Toronto, Canada (the BeMORE collaboration). "After studying the data we concluded that first trimester exposure to folic acid antagonists is associated with increased risk for neural tube, cardiovascular and urinary tract defects," says paediatrician and clinical pharmacologist Rafael Gorodischer. Healthcare professionals now encourage women to take folic acid supplements or eat food fortified with folic acid if they are planning to get pregnant as well as during early pregnancy, because there is clear evidence that this reduces the risk of any resulting baby having neural tube defects and possibly other birth defects (congenital malformations). The team considered the effects of two groups of medications on pregnancy. Each group consists of drugs that prevent folic acid working in the body. One group (dihydrofolate reductase inhibitors), prevents folate being converted into its active metabolites and includes trimethoprim, sulfasalazine and methotrexate. The other medications are known to lower serum and tissue concentrations of folate by various mechanisms, and include antiepileptics (carbamazepine, phenytoin, lamotrigine, primidone, valproic acid and phenobarbital), and cholestyramine. "The study shows that exposure to folic acid antagonists in the first trimester of pregnancy, more than doubled the risk of congenital malformations in the fetus, and that neural tube defects, such as spina bifida and malformations of the brain, are increased by more than six fold after exposure to these antagonists," said epidemiologist Dr. Amalia Levy. "Clinicians should try to avoid the use of these drugs whenever possible in women contemplating pregnancy," concluded Gorodischer. This content has passed through fivefilters.org. |
INSIDE STORY: Padma Lakshmi's 'Miracle Pregnancy' - People Posted: 13 Oct 2009 04:07 PM PDT For Top Chef's season 4 competitors, news of Padma Lakshmi's pregnancy came as no surprise. Spike Mendelsohn recalls that when another contestant, Antonia Lofaso, started to cry because she missed her daughter, "out of nowhere, Padma started to tear up also. It signified something to us."
But for Lakshmi, 39, conceiving a child was the fulfillment of a wish she once thought would be impossible. Earlier this year the cookbook author, jewelry designer and actress co-founded the Endometriosis Foundation of America, and revealed that she had undergone two surgeries for endometriosis. The condition, in which tissues lining the uterus grow outside the uterus, is a common contributor to infertility. "If you have stage 1 or 2 endometriosis, it may decrease fertility by 10 to 15 percent," says Dr. Andrea Rapkin, a professor of obstetrics and gynecology at the David Geffen School of Medicine at UCLA. "If you have stage 3 or 4 endometriosis, which affects the fallopian tubes, the fertility rate even after surgery can be under 20 percent." (Laksmhi hasn't revealed what level endometriosis she has, though experts say doctors typically only operate on stages 3 or 4.) Fancy Meals for BabyLast week on Regis and Kelly, Lakshmi said that as a result of her condition, she waited as long as she could to share her happy news. "It was a little touch and go," she said. "But everything's fabulous. Now that I told everyone, I think my body has relaxed and I've just got this little Buddha belly!"That belly – which Lakshmi told PEOPLE gets slathered in butter daily – is being nourished with some haute cuisine. In recent days, Lakshmi has catalogued her meals on her Twitter page, ranging from chilequiles with refried green enchiladas and green apple mint chutney to mangoes grown in her mother's garden. Father a MysteryFor now Lakshmi, who divorced author Salman Rushdie in 2007, is keeping mum about the identity of her baby's father-except to say it isn't her frequent companion Manu Nathan, who she says is "a cousin and dear friend."Raised chiefly by her mother Vijaya in India and New York City, Lakshmi has a strong example of a single mother should she be facing motherhood on her own."If she happens to be a single mother," says Mendelsohn, the chef and owner of Washington, D.C.'s Good Stuff Eatery. "She is definitely one of the women capable of doing that without a problem," he says. "She's well traveled, she's seen the world, she's embraced different cultures, and she's really into food and cooking. She's going to nurture her child in those ways." Fellow contestant Nikki Cascone adds, "I'm sure that baby will be well fed, and well loved!" Reporting by LIZA HAMM, NATASHA STOYNOFF and ALYSSA SHELASKY This content has passed through fivefilters.org. |
LETTER: Some of us do know the facts - Lufkin Daily News Posted: 13 Oct 2009 10:20 PM PDT Re: Michelle Green. In your guest letter to the papers you said. ''it's important to note that the statistics Michelle Reynolds mentioned in her letter are difficult to prove and others are simply false.'' First of all right after you tell us she presents no proof of the statistics, you follow that up with slander of the peaceful protests, claiming things were happening without telling us where these things were happening so your claims are just that — unproven claims. You also say Reynolds is correct that Planned Parenthood health centers provide Plan B, also known as Emergency Contraception. It's false that Plan B/Emergency Contraception is an "abortificant." Plan B/Emergency Contraception is birth control and can prevent a pregnancy up to five days after unprotected intercourse. It cannot cause an abortion and it has no effect on a pregnancy.'' Might I bring to your attention a statement on the morningafterpill.org. Emergency contraception, essentially, is a high dosage of the birth control pill. It is recommended for use after sexual intercourse, over a period of 72 hours, to achieve the goal of preventing pregnancy. Also, if it has no affect on pregnancy why would they take it? And of course my favorite, ''Her claims about Planned Parenthood are also untrue. I understand that abortion is a divisive issue. My hope is that as reasonable people, we can agree to disagree about abortion. Above all, we should stick to the facts.'' I may be wrong, but I do believe your agreeing to disagree is telling those of us who know the facts to shut up and just let you say what you want. Unfortunately some of us do know the facts. This content has passed through fivefilters.org. |
Basilea's Toctino - Market Wire Posted: 13 Oct 2009 10:20 PM PDT SOURCE: Basilea Pharmaceutica AG BASEL, SWITZERLAND--(Marketwire - October 14, 2009) - "We are delighted that this innovative Basilea drug received marketing authorization in our home market. Toctino is the first licensed treatment for patients suffering from severe chronic hand eczema who do not respond to potent steroid therapy," said Dr. Anthony Man, CEO of Basilea. "We look forward to bring Toctino to patients and physicians in Switzerland soon." Basilea submitted a pricing and reimbursement dossier to the Swiss authorities. Toctino® has been launched in Denmark, Germany and the United Kingdom for the treatment of adults with severe chronic hand eczema unresponsive to potent topical corticosteroids. Toctino® has also received marketing authorization in Austria, Belgium, Finland, France, Luxemburg, the Netherlands and Spain. Further, Toctino® has been recommended for approval in Italy. Alitretinoin is under regulatory review in Canada and 15 additional European countries. Chronic hand eczema - a debilitating skin disease Hand eczema is a common inflammatory skin disease and is often chronic and relapsing. Hand eczema is reported to affect up to ten percent of the general population across Europe. It is characterized by thick, scaly skin that commonly gives rise to blisters, redness, swelling and painful cracks in the skin. The more severe, chronic form of the condition is thought to affect five to seven percent of these patients, causing impaired use of their hands and a considerable impact on their ability to perform everyday activities. Toctino® (alitretinoin), the only therapy approved for severe chronic hand eczema unresponsive to potent topical treatments Toctino® was developed by Basilea Pharmaceutica International Ltd. Swissmedic approved Toctino® for the use in adults who have severe refractory chronic hand eczema that is unresponsive to at least 4 weeks of extended topical treatment. The initial treatment includes the avoidance of contact to the causative irritant/noxa, skin protection and potent topical corticosteroids. Toctino® (alitretinoin) is a once-daily capsule to be taken with food. The recommended starting dose is 30 mg in most patients and a treatment course lasts up to 24 weeks depending on response. Alitretinoin is a naturally occurring, physiologic retinoid that is thought to work in CHE through anti-inflammatory and immunomodulatory effects. Alitretinoin is a known teratogen (a substance that can cause birth defects when women are exposed during pregnancy). Strict pregnancy prevention one month before, during, and one month after cessation of treatment as well as monthly pregnancy testing are required for women of childbearing age. A comprehensive pregnancy prevention program has been developed and implemented. In clinical trials alitretinoin was well tolerated and has a safety profile overall consistent with the retinoid class. Side effects were generally dose-dependent. About Basilea Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange ( SWISS : BSLN). Basilea's integrated research and development operations are currently focused on new antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including two commercialized drugs (Toctino®, ZEFTERA™/ Zevtera™) and one investigational drug in phase III (isavuconazole). Toctino® (alitretinoin) is marketed in the United Kingdom, Denmark and Germany and is approved in Austria, Belgium, Finland, France, Luxemburg, the Netherlands, Spain and Switzerland. Alitretinoin has been recommended for approval in Italy and is under regulatory review in Canada and 15 additional European countries. Furthermore a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. Ceftobiprole is marketed in Canada under the brand name ZEFTERA™ and in Switzerland under Zevtera™. Ceftobiprole is under regulatory review in the U.S., in the EU and several other countries. The company has set up commercial organizations in UK, Denmark, Germany and Canada, while it is building sales and marketing organizations in other countries to commercialize alitretinoin and to co-promote ceftobiprole, subject to approval. Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact:
+--------------------------------------------------------------+ | Media Relations | Investor Relations | |-----------------------------+--------------------------------| | Adesh Kaul | Barbara Zink, Ph.D. | | Head Public Relations & | Head Corporate Development | | Corporate Communications | | | +41 61 606 1460 | +41 61 606 1233 | | media_relations@basilea.com | investor_relations@basilea.com | +--------------------------------------------------------------+ This press release can be downloaded from www.basilea.com The press release can also be downloaded from the following link: http://hugin.info/134390/R/1347329/323911.pdf
Copyright © Hugin AS 2009. All rights reserved. This content has passed through fivefilters.org. |
You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google Inc., 20 West Kinzie, Chicago IL USA 60610 |
No comments:
Post a Comment